Acomplia To Launch In July In Europe For Obesity Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis’ rimonabant is currently “approvable” at FDA for obesity.
You may also be interested in...
Suicide Associated With Sanofi-Aventis’ Acomplia, U.K. Agency Says
One suicide and 48 suicidal ideation cases reported following treatment with Acomplia between June 2006 and May 9.
Suicide Associated With Sanofi-Aventis’ Acomplia, U.K. Agency Says
One suicide and 48 suicidal ideation cases reported following treatment with Acomplia between June 2006 and May 9.
Sanofi-Aventis’ Rimonabant Cuts Visceral Fat
ADAGIO-LIPIDS trial shows HDL cholesterol boost but not LDL.